Clinical Trials at Asheville Hematology-Oncology Associates
During the past decade, Asheville Hematology-Oncology Associates conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 13 clinical trials were completed, i.e. on
average, 325% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 8 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
2008-06-15
2015-05-28
Completed
210
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Asheville Hematology-Oncology Associates"
#1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator and "Roche-Genentech" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Asheville Hematology-Oncology Associates
According to Clinical.Site data, the most researched conditions in "Asheville Hematology-Oncology Associates" are
"Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials), "ATM Gene Mutation" (1 trials), "ATR Gene Mutation" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "Asheville Hematology-Oncology Associates" in a lesser frequency.
Clinical Trials Intervention Types at Asheville Hematology-Oncology Associates
Most popular intervention types in "Asheville Hematology-Oncology Associates" are "Drug" (13 trials), "Other" (13 trials), "Biological" (5 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (11 trials), "Docetaxel" (3 trials), "Durvalumab" (2 trials), "Quality-of-Life Assessment" (2 trials) and "Afatinib Dimaleate" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Asheville Hematology-Oncology Associates
The vast majority of trials in "Asheville Hematology-Oncology Associates" are
15 trials for "All" genders.
Clinical Trials Status at Asheville Hematology-Oncology Associates
Currently, there are NaN active trials in "Asheville Hematology-Oncology Associates".
undefined are not yet recruiting,
undefined are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 10 completed trials in Asheville Hematology-Oncology Associates,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Asheville Hematology-Oncology Associates, 0 "Phase 1"
clinical trials were conducted, 11 "Phase 2" clinical
trials and 8 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".